Evidence map›Paper›PMID 41944851›Full record

ArticleAnnals of hematology2026

Long enduring response on teclistamab in a patient with myeloma relapse after allogeneic hematopoietic stem cell transplantation - a case report.

P Ebner, J Fauser, G Hetzenauer, S Köck, W Willenbacher, L M Rossetti, T A Buchwald, L Rasche, E Gunsilius, D Nachbaur and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

P EbnerUniversity Hospital of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Anichstraße, 35, Innsbruck, 6020, Austria.
J FauserUniversity Hospital of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Anichstraße, 35, Innsbruck, 6020, Austria.
G HetzenauerUniversity Hospital of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Anichstraße, 35, Innsbruck, 6020, Austria.
S KöckUniversity Hospital of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Anichstraße, 35, Innsbruck, 6020, Austria.
W WillenbacherUniversity Hospital of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Anichstraße, 35, Innsbruck, 6020, Austria.
L M RossettiDepartment of Nuclear Medicine, Medical University of Innsbruck, Anichstraße 35, Innsbruck, 6020, Austria.
T A BuchwaldDepartment of Internal Medicine II, University Hospital of Würzburg, Grombühlstraße 12, 97080, Grombühl, Würzburg, Germany.
L RascheDepartment of Internal Medicine II, University Hospital of Würzburg, Grombühlstraße 12, 97080, Grombühl, Würzburg, Germany.
E GunsiliusUniversity Hospital of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Anichstraße, 35, Innsbruck, 6020, Austria.
D NachbaurUniversity Hospital of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Anichstraße, 35, Innsbruck, 6020, Austria.
D WolfUniversity Hospital of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Anichstraße, 35, Innsbruck, 6020, Austria.
N SteinerUniversity Hospital of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Anichstraße, 35, Innsbruck, 6020, Austria. normann.steiner@i-med.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular based therapies, such as bispecific T-cell engagers (TCE), have changed the landscape of myeloma treatment, but to the present day little is known about the use of these therapies in patients with prior allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this case report, we present a patient with multi-refractory multiple myeloma (MM), who relapsed after allo-HSCT and anti-SLAMF-7-CART-cell-therapy and was ultimately successfully treated with teclistamab, a BCMA-directed TCE, and we discuss theoretical considerations based on present literature about possible underlying immunological mechanisms, that might have contributed to a long enduring treatment response.

Indexed as

Antibodies, BispecificHematopoietic Stem Cell TransplantationMultiple MyelomaHumansMaleMiddle AgedRecurrenceTransplantation, HomologousAntibodies, BispecificGraft versus myeloma effectLong-enduring treatment responseRelapsed/refractory myelomaTCE after allo-HSCTTeclistamab

Identifiers

PMID41944851
PMCPMC13056730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.